NeuroOne Medical Technologies (NMTC) AI Stock Analysis

• Market Cap: $40.40M
• Dividend Yield: N/A
• Average Volume (3M): 200.15K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.28
• Revenue Growth: 135.03%
• EPS Growth: 60.67%
• Country: US
• Employees: 17
• Sector: Healthcare
• Sector Strength: 38
• Industry: Medical - Devices
• EPS (TTM): -0.07
• Shares Outstanding: 49,817,837
• 10 Day Avg. Volume: 221,915
• 30 Day Avg. Volume: 200,151
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.63
• Enterprise Value/Revenue: 4.42
• Enterprise Value/Gross Profit: 8.15
• Enterprise Value/Ebitda: -4.45
• 1Y Price Target: $1.45
• Price Target Upside: 76.83% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 56 Neutral
• Price Target: $1.00 ▲(21.95% Upside)

NeuroOne Medical Technologies has a promising revenue growth trajectory and improving gross margins, as highlighted in the earnings call. However, the ongoing net losses, negative valuation metrics, and Nasdaq non-compliance notice present significant challenges. The company's strong liquidity and strategic initiatives provide a buffer, but profitability improvements are crucial for future success.

NeuroOne Medical Technologies Business Overview & Revenue Model

Company Description

NeuroOne Medical Technologies (NMTC) is a medical technology company focused on developing and commercializing innovative thin-film electrode technology for neurosurgical applications. The company's core products are designed to improve outcomes for patients suffering from a variety of neurological disorders. NeuroOne's solutions aim to enhance the performance of traditional brain and nervous system surgeries, including diagnostic monitoring, brain stimulation, and ablation procedures.

How the Company Makes Money

NeuroOne Medical Technologies makes money primarily through the development, manufacturing, and sales of its thin-film electrode technology used in neurological procedures. The company's revenue model includes direct sales to hospitals and healthcare facilities, as well as collaborations with medical device companies and partnerships for co-development and distribution of its technologies. NeuroOne may also generate revenue from licensing its proprietary technology and intellectual property. Additionally, the company benefits from strategic partnerships that enhance its market reach and development capabilities.

NeuroOne Medical Technologies Financial Statement Overview

Summary

NeuroOne Medical Technologies is experiencing rapid revenue growth but faces significant profitability challenges, with persistent operational losses. The balance sheet shows low leverage and strong liquidity, yet continuous net losses threaten equity sustainability. Despite improvements in cash flow, the company must enhance operational efficiency to improve margins and profitability.

Income Statement

NeuroOne Medical Technologies has shown a significant increase in revenue over the Trailing-Twelve-Months (TTM), with revenue growing from $3.45 million to $1.39 billion. However, the company continues to face substantial profitability challenges, with negative EBIT and net income margins, indicating ongoing operational losses. The gross profit margin is positive, but the high level of operating expenses is impacting net profitability.

Balance Sheet

The balance sheet of NeuroOne is moderately leveraged with a debt-to-equity ratio of 0.18, indicating a conservative use of debt. The company's equity ratio stands at 25.3%, reflecting a solid base of equity relative to total assets. However, the continuous net losses are a concern for the sustainability of equity. Cash holdings are strong, providing liquidity support.

Cash Flow

The company has shown improvement in operating cash flow, turning positive in the TTM, which is a positive indicator of operational efficiency. However, the free cash flow has only recently become positive, and historical negative free cash flow highlights cash flow management challenges. The operating cash flow to net income ratio suggests that cash generation is better than what income figures indicate.

Breakdown	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	3.45M	1.95M	171.17K	178.15K	1.93M
Gross Profit	1.08M	456.52K	-70.79K	-97.75K	63.12K
EBITDA	-11.84M	-11.76M	-9.91M	-9.80M	-4.85M
Net Income	-12.32M	-11.86M	-10.00M	-9.95M	-13.64M
Balance Sheet
Total Assets	5.37M	8.10M	12.82M	7.94M	4.76M
Cash, Cash Equivalents and Short-Term Investments	1.46M	5.32M	11.14M	6.90M	4.04M
Total Debt	260.16K	184.40K	202.90K	315.67K	1.32M
Total Liabilities	4.55M	1.85M	3.22M	1.38M	2.69M
Stockholders Equity	822.01K	6.25M	9.60M	6.55M	2.07M
Cash Flow
Free Cash Flow	-11.13M	-13.27M	-7.79M	-8.67M	-3.55M
Operating Cash Flow	-11.01M	-12.89M	-7.52M	-8.60M	-3.43M
Investing Cash Flow	-120.20K	2.65M	-3.24M	-67.08K	-122.43K
Financing Cash Flow	7.27M	7.40M	12.02M	11.53M	7.32M

NeuroOne Medical Technologies Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.82
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NMTC, the sentiment is Positive. The current price of 0.82 is above the 20-day moving average (MA) of 0.81, above the 50-day MA of 0.71, and below the 200-day MA of 0.82, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 52.74 is Neutral, neither overbought nor oversold. The STOCH value of 28.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NMTC.

NeuroOne Medical Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NMTC	56 Neutral	$40.40M	―	-265.18%	―	135.03%	60.67%
Sector *	51 Neutral	$7.39B	0.42	-62.86%	2.37%	15.61%	-1.95%
PAVM	46 Neutral	$8.47M	0.69	-499.57%	―	-33.92%	―
COCH	45 Neutral	$31.85M	―	1697.39%	―	-26.49%	-91.23%
RBOT	39 Underperform	$54.87M	―	-104.36%	―	―	-1455.58%
IINN	35 Underperform	$32.79M	―	-196.69%	―	―	―

NeuroOne Medical Technologies Corporate Events

NeuroOne Advances with FDA Submission and Capital Raise

On May 13, 2025, NeuroOne Medical Technologies reported significant progress in its operations for the second quarter of fiscal year 2025. The company successfully filed an FDA submission for its OneRF® Trigeminal Nerve Ablation System ahead of schedule, potentially leading to revenue generation by late 2025. Additionally, NeuroOne completed an $8.2 million capital raise, ensuring funding through fiscal year 2026, and strengthened its management team. The company’s product revenue guidance for fiscal year 2025 is projected to increase significantly, with potential strategic partnerships in development for further applications of its technology.

The most recent analyst rating on (NMTC) stock is a Buy with a $1.45 price target. To see the full list of analyst forecasts on NeuroOne Medical Technologies stock, see the NMTC Stock Forecast page.

NeuroOne Faces Nasdaq Non-Compliance Notice

On May 6, 2025, NeuroOne Medical Technologies received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement, as its stock price was below $1.00 for 30 consecutive business days. The company has until November 3, 2025, to regain compliance or risk delisting, and is actively monitoring its stock price while considering options to address the issue.